{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:22:00Z","timestamp":1774578120811,"version":"3.50.1"},"reference-count":92,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,2]],"date-time":"2016-01-02T00:00:00Z","timestamp":1451692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["tzuchimedjnl.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tzu Chi Medical Journal"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.tcmj.2015.12.003","type":"journal-article","created":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T14:45:55Z","timestamp":1453733155000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Practical points in the medical treatment of overactive bladder and\u00a0nocturia in the elderly"],"prefix":"10.4103","volume":"28","author":[{"given":"Jing-Liang","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.tcmj.2015.12.003_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/nau.21036","volume":"308","author":"Haylen","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.tcmj.2015.12.003_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2012.04.004","article-title":"Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS","volume":"80","author":"Milsom","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.tcmj.2015.12.003_bib3","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.eururo.2010.03.014","article-title":"Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: a longitudinal population-based survey in men aged 45\u2013103 years","volume":"58","author":"Malmsten","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1532-5415.2000.tb04744.x","article-title":"Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group","volume":"48","author":"Brown","year":"2000","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.tcmj.2015.12.003_bib6","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1046\/j.1532-5415.2002.50455.x","article-title":"Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study","volume":"50","author":"Leibson","year":"2002","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.tcmj.2015.12.003_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afi205","article-title":"Urinary storage symptoms and comorbidities: a prospective population cohort study in middle-aged and older women","volume":"35","author":"McGrother","year":"2006","journal-title":"Age Ageing"},{"key":"10.1016\/j.tcmj.2015.12.003_bib8","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.ajog.2004.11.033","article-title":"Nocturnal polyuria in women with overactive bladder symptoms and nocturia","volume":"192","author":"Drake","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.urology.2011.10.020","article-title":"High classification of chronic heart failure increases risk of overactive bladder syndrome and lower urinary tract symptoms","volume":"79","author":"Chiu","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.tcmj.2015.12.003_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijgo.2010.03.007","article-title":"A\u00a0noninvasive evaluation of autonomic nervous system dysfunction in women with an overactive bladder","volume":"110","author":"Liao","year":"2010","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.tcmj.2015.12.003_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1540-8159.2004.00431.x","article-title":"Heart rate variability and diastolic heart failure","volume":"27","author":"Arora","year":"2004","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1464-410X.2005.05392.x","article-title":"Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy","volume":"95","author":"Yoshimura","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.tcmj.2015.12.003_bib13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fphar.2010.00136","article-title":"Bladder dysfunction in diabetes mellitus","volume":"1","author":"Golbidi","year":"2010","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/j.1442-2042.2012.03095.x","article-title":"Higher glycosylated hemoglobin levels increase the risk of overactive bladder syndrome in patients with type 2 diabetes mellitus","volume":"19","author":"Chiu","year":"2012","journal-title":"Int J Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/nau.22429","article-title":"The prevalence and risk factors of OAB in middle-aged and old people in China","volume":"33","author":"Wen","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.tcmj.2015.12.003_bib16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinics treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib17","first-page":"1288","article-title":"Bladder afferent signaling: recent findings","volume":"183","author":"Kanai","year":"2010","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib18","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.urology.2007.11.145","article-title":"Development of idiopathic detrusor underactivity in women: from isolated decrease in contraction velocity to obvious impairment of voiding function","volume":"71","author":"Cucchi","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.tcmj.2015.12.003_bib19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.eururo.2010.11.040","article-title":"Antimuscarinic mechanisms and the overactive detrusor: an update","volume":"59","author":"Andersson","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1113\/jphysiol.2013.262634","article-title":"Age-related changes in afferent pathways and urothelial function in the male mouse bladder","volume":"592","author":"Daly","year":"2014","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib21","first-page":"434","article-title":"Involvement of TL1A and DR3 in induction of ischaemia and inflammation in urinary bladder dysfunction in the elderly","volume":"6","author":"Wang","year":"2012","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.tcmj.2015.12.003_bib22","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.urology.2014.05.017","article-title":"Is type-2 diabetes mellitus associated with overactive bladder symptoms in men with lower urinary tract symptoms?","volume":"84","author":"Bang","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.tcmj.2015.12.003_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/ncpuro0021","article-title":"Mechanisms of disease: central nervous system involvement in overactive bladder syndrome","volume":"1","author":"Andersson","year":"2004","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/iju.12288","article-title":"Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly","volume":"21","author":"Sakakibara","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000353274","article-title":"Systematic review of the epidemiology of urinary incontinence and detrusor overactivity among patients with neurogenic overactive bladder","volume":"41","author":"Ruffion","year":"2013","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.tcmj.2015.12.003_bib26","first-page":"1507","article-title":"Bladder function in elderly men with subclinical brain magnetic resonance imaging lesions","volume":"147","author":"Kitada","year":"1992","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-7525-11-13","article-title":"Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review","volume":"11","author":"Tapia","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.tcmj.2015.12.003_bib28","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/j.1532-5415.2005.00537.x","article-title":"Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients","volume":"53","author":"Kay","year":"2005","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.tcmj.2015.12.003_bib29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib30","first-page":"1804","article-title":"Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity","volume":"189","author":"Liao","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib31","first-page":"2455","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline","volume":"188","author":"Gormley","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib32","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","article-title":"Muscarinic receptor antagonists for overactive bladder","volume":"100","author":"Abrams","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.tcmj.2015.12.003_bib33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/pcan.2011.22","article-title":"Initial combined treatment with anticholinergics and \u03b1-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study","volume":"14","author":"Lee","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.tcmj.2015.12.003_bib34","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/j.1464-410X.2011.10624.x","article-title":"Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving \u03b1-blocker treatment for lower urinary tract symptoms","volume":"109","author":"Kaplan","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.tcmj.2015.12.003_bib35","first-page":"2825","article-title":"Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency","volume":"182","author":"Kaplan","year":"2009","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib36","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eururo.2006.02.018","article-title":"A\u00a0shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder","volume":"49","author":"Chapple","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib37","first-page":"2253","article-title":"Combination treatment with an alphablocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study","volume":"169","author":"Athanasopoulos","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib38","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2004.05039.x","article-title":"Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder","volume":"94","author":"Lee","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.tcmj.2015.12.003_bib39","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolterodine and tamsulosine for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial","volume":"296","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.tcmj.2015.12.003_bib40","first-page":"1793","article-title":"Update on AUA guideline on the management of benign prostatic hyperplasia","volume":"185","author":"McVary","year":"2011","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib41","article-title":"Guidelines on nonneurogenic male LUTS","author":"Oelke","year":"2011","journal-title":"Uroweb"},{"key":"10.1016\/j.tcmj.2015.12.003_bib42","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1742-1241.2011.02638.x","article-title":"Diagnostic value of International Prostate Symptom Score voiding-to-storage subscore ratio in male lower urinary tract symptoms","volume":"65","author":"Liao","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.tcmj.2015.12.003_bib43","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.urology.2013.01.018","article-title":"Predictors of successful first-line antimuscarinic monotherapy in men with enlarged prostate and predominant storage symptoms","volume":"81","author":"Liao","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.tcmj.2015.12.003_bib44","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/00002512-200522120-00003","article-title":"Overactive bladder in the elderly: a guide to pharmacological management","volume":"22","author":"Staskin","year":"2005","journal-title":"Drugs Aging"},{"key":"10.1016\/j.tcmj.2015.12.003_bib45","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/iju.12298","article-title":"Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study","volume":"21","author":"Akino","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib46","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.eururo.2014.07.013","article-title":"Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE study and NEPTUNE II open-label extension","volume":"67","author":"Drake","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib47","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.clinthera.2005.02.014","article-title":"Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly","volume":"27","author":"Scheife","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.tcmj.2015.12.003_bib48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11597530-000000000-00000","article-title":"Blood\u2013brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder","volume":"29","author":"Chancellor","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.tcmj.2015.12.003_bib49","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/ijcp.12447","article-title":"Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence?","volume":"68","author":"Gibson","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.tcmj.2015.12.003_bib50","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/ijcp.12483","article-title":"Persistence with solifenacin add-on therapy in men with benign prostate obstruction and residual symptoms of overactive bladder after tamsulosin monotherapy","volume":"68","author":"Lee","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.tcmj.2015.12.003_bib51","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1742-1241.2010.02626.x","article-title":"Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature","volume":"65","author":"Sexton","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.tcmj.2015.12.003_bib52","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1464-410X.2012.11023.x","article-title":"Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience","volume":"110","author":"Wagg","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.tcmj.2015.12.003_bib53","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/aogs.12196","article-title":"Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database","volume":"92","author":"Mauseth","year":"2013","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.tcmj.2015.12.003_bib54","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.08.060","article-title":"Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses","volume":"62","author":"Buser","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib55","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2013.01.002","article-title":"Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study","volume":"64","author":"Wagg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib56","first-page":"395","article-title":"Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial","volume":"191","author":"Dubeau","year":"2014","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib57","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1464-410X.2006.06677.x","article-title":"Overactive bladder syndrome in older people","volume":"99","author":"Wagg","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.tcmj.2015.12.003_bib58","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/nau.20923","article-title":"The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia","volume":"30","author":"Chung","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.tcmj.2015.12.003_bib59","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.urology.2011.02.055","article-title":"Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms\u2014ASSIST, randomized controlled study","volume":"78","author":"Yamaguchi","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.tcmj.2015.12.003_bib60","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5213\/inj.2013.17.4.191","article-title":"Maintenance of the therapeutic effect of two high-dosage antimuscarinics in the management of overactive bladder in elderly women","volume":"17","author":"Kosilov","year":"2013","journal-title":"Int Neurourol J"},{"key":"10.1016\/j.tcmj.2015.12.003_bib61","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib62","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1464-410X.2008.07761.x","article-title":"Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score","volume":"102","author":"Kaplan","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.tcmj.2015.12.003_bib63","first-page":"1034","article-title":"Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms","volume":"180","author":"Rovner","year":"2008","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib64","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1742-1241.2010.02611.x","article-title":"Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review","volume":"65","author":"Kaplan","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.tcmj.2015.12.003_bib65","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.106.115840","article-title":"Effect of (R)-2-(2-aminothiazol-4-yl)-4\u2032-{2-[(2-hydroxy-2-phenylethyl) amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function","volume":"321","author":"Takasu","year":"2007","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.tcmj.2015.12.003_bib66","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/bju.12730","article-title":"Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a \u03b23-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB)","volume":"115","author":"Rossanese","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.tcmj.2015.12.003_bib67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2490-13-45","article-title":"Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European\u2013Australian Phase 3 trial","volume":"13","author":"Khullar","year":"2013","journal-title":"BMC Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib68","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/ijcp.12194","article-title":"Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies","volume":"67","author":"Nitti","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.tcmj.2015.12.003_bib69","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European\u2013Australian Phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib70","first-page":"1388","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib71","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b23-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib72","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/bju.12649","article-title":"Phase III, randomised, double-blind, placebo-controlled study of the \u03b23-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder","volume":"113","author":"Yamaguchi","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.tcmj.2015.12.003_bib73","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/nau.22645","article-title":"Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder in Asia","volume":"34","author":"Kuo","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.tcmj.2015.12.003_bib74","first-page":"1320","article-title":"Urodynamics and safety of the \u03b2-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction","volume":"190","author":"Nitti","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib75","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/ageing\/afu017","article-title":"The efficacy and tolerability of the \u03b23-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients","volume":"43","author":"Wagg","year":"2014","journal-title":"Age Ageing"},{"key":"10.1016\/j.tcmj.2015.12.003_bib76","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.urology.2012.03.049","article-title":"Importance of relieving the most bothersome symptom for improving quality of life in male patients with lower urinary tract symptoms","volume":"80","author":"Lee","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.tcmj.2015.12.003_bib77","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.eururo.2012.07.004","article-title":"A\u00a0contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management\u2014a systematic review and meta-analysis","volume":"62","author":"Cornu","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib78","first-page":"552","article-title":"Pathophysiological aspects of nocturia in a Danish population of men and women age 60 to 80 years","volume":"178","author":"Bing","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib79","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.archger.2005.04.003","article-title":"Nocturia and the burning mouth syndrome (BMS) in the elderly","volume":"41","author":"Asplund","year":"2005","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.tcmj.2015.12.003_bib80","first-page":"548","article-title":"Age related pathogenesis of nocturia in patients with overactive bladder","volume":"178","author":"Weiss","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib81","first-page":"2671","article-title":"Gender differences in nighttime plasma arginine vasopressin and delayed compensatory urine output in the elderly population after desmopressin","volume":"178","author":"Hvistendahl","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib82","doi-asserted-by":"crossref","first-page":"E891","DOI":"10.1111\/j.1464-410X.2012.11467.x","article-title":"Association of symptoms with urodynamic findings in men with overactive bladder syndrome","volume":"110","author":"Al-Zahrani","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.tcmj.2015.12.003_bib83","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.urology.2004.12.031","article-title":"Nocturia in men with lower urinary tract symptoms is associated with both nocturnal polyuria and detrusor overactivity with positive response to ice water test","volume":"65","author":"Hirayama","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.tcmj.2015.12.003_bib84","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/smrv.2002.0273","article-title":"Sleep disordered breathing and nocturnal polyuria: nocturia and enuresis","volume":"7","author":"Umlauf","year":"2003","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.tcmj.2015.12.003_bib85","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2169\/internalmedicine.44.281","article-title":"Nocturnal polyuria with abnormal circadian rhythm of plasma arginine vasopressin in post-stroke patients","volume":"44","author":"Sakakibara","year":"2005","journal-title":"Intern Med"},{"key":"10.1016\/j.tcmj.2015.12.003_bib86","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1464-410X.2004.05003.x","article-title":"Antidiuretic hormone in elderly male patients with severe nocturia: a circadian study","volume":"94","author":"Moon","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.tcmj.2015.12.003_bib87","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1464-410X.2002.02791.x","article-title":"Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men","volume":"89","author":"Mattiasson","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.tcmj.2015.12.003_bib88","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.eururo.2007.01.027","article-title":"Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study","volume":"52","author":"van Kerrebroeck","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib89","first-page":"180","article-title":"Desmopressin add-on therapy for refractory nocturia in men receiving \u03b1-blockers for lower urinary tract symptoms","volume":"190","author":"Bae","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.tcmj.2015.12.003_bib90","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0090-4295(01)01645-4","article-title":"Efficacy of desmopressin in treatment of refractory nocturia in patients older than 65 years","volume":"59","author":"Kuo","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.tcmj.2015.12.003_bib91","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/nau.20168","article-title":"Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia","volume":"25","author":"Rembratt","year":"2006","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.tcmj.2015.12.003_bib92","first-page":"200","article-title":"The effects of long-term administration of oral desmopressin on the baseline secretion of antidiuretic hormone and serum sodium concentration for the treatment of nocturia: a circadian study","volume":"178","author":"Bae","year":"2007","journal-title":"J\u00a0Urol"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1016319015001147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1016319015001147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T23:29:48Z","timestamp":1718321388000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1016319015001147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1016319015001147"],"URL":"https:\/\/doi.org\/10.1016\/j.tcmj.2015.12.003","relation":{},"ISSN":["1016-3190"],"issn-type":[{"value":"1016-3190","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical points in the medical treatment of overactive bladder and\u00a0nocturia in the elderly","name":"articletitle","label":"Article Title"},{"value":"Tzu Chi Medical Journal","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.tcmj.2015.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}